Abiogen Pharma S.p.A.

ABIOGEN PHARMA: FIVE GENERATIONS OF EXELLENCE

Abiogen Pharma is a privately owned specialist pharmaceutical company focused on bone metabolism and some rare diseases. The Company was founded in 1997 by Massimo Di Martino who decided to maintain the family’s tradition alive after the sale of Istituto Gentili, founded by his great grandfather Alfredo Gentili, to Merck Sharp & Dohme.

Today,it represents a highly successful family business reality that boasts a position among the top 30 pharmaceutical companies in Italy.

Abiogen Pharma now operates on three integrated areas of activity:

• research and development
• the production of its own and customers’ products
• the marketing of its own and in license products

Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies and has reached millions of patients globally.

Ascendis Pharma

Ascendis Pharma is delighted to be participating in ECTS 2022!
Founded in 2007 to leverage the innovative TransCon® technology to make a meaningful difference for patients, we are a dynamic, growing biopharma company with offices in Denmark, Germany and the United States. We’re advancing programs and product candidates in both endocrinology and in oncology.
Ascendis is a sponsor of ECTS 2022. Please visit our booth in the Exhibition Hall, and online at Ascendis-ECTS.com
Join us for Ascendis’ Oral Presentation, “Efficacy and Safety With TransCon PTH for Adults With Hypoparathyroidism Through Week 84 in the PaTH Forward Trial.“ 

Blueprint Genetics 

Blueprint Genetics, a Quest Diagnostics company, is a leading specialty genetics and bioinformatics company focused on inherited diseases. With a patient-first mindset, we deliver high-quality genetic testing to the global clinical community across 15 medical specialties. Our superior capabilities in difficult-to-sequence regions, high-resolution CNV detection, clinically relevant non-coding variants and the availability of mitochondrial analysis bring you the most comprehensive genetic test on the market. Blueprint Genetics is based in Helsinki and Seattle with a customer base spanning over 70 countries. www.blueprintgenetics.com.  

Bruker Biospin GmbH

Bruker-MicroCT develops and manufactures micro and nano-CT scanners both in vivo and ex vivo, with the highest resolution and imaging performance over both categories. Bruker SkyScan scanners have been essential tools for bone researchers for more than 2 decades. In-vivo imaging with physiological monitoring is within proven safe dose limits. Scanners are supplied with comprehensive analysis software featuring high speed GPU reconstruction, versatile volume of interest selection tools including trabecular-cortical separation, calibrated BMD/TMD, comprehensive 3d and 2d parameters (ASBMR-compliant) and customisable batch operations. In-depth bone research and morphometry support is provided. Bruker-MicroCT customers are closely supported by 66 distributors worldwide.

Calciscon

Calciscon (Switzerland) markets breakthrough diagnostic solutions to assess and improve everyone’s Calcification-related Cardiovascular Risk. Managing vascular calcification is a critical concern for avoiding cardiovascular (CV) complications. The T50® test is the first and only blood test to measure calcification propensity, providing a unique, functional insight into the physiological mineral buffer system.

T50 has been extensively studied in kidney patients (13,000+ patients) and the general population (6000+ participants), and was consistently found to independently predict CV events and death. The medical community has now started to investigate T50 in CV population, and other diseases known to be affected by calcification.

European Calcified Tissue Society (ECTS)

The European Calcified Tissue Society (ECTS) is the major organisation in Europe for researchers and clinicians working in the field of calcified tissues and related fields. For over 50 years the Society has acted as a forum to promote the highest levels of knowledge, research and education through its annual meetings, training courses and grants and awards. Membership of the ECTS is open to anyone working in the field at whatever stage in their career. Come and meet us in Budapest at our booth.
www.ectsoc.org
 

Elsevier

Elsevier journals in the musculoskeletal field provide a stage for global research collaboration. Our journals, broad ranging in scope, serve the research needs of educators, clinicians, researchers and students forging developments and discoveries with significant real-world impacts. Browse our journals and books here: https://www.sciencedirect.com/browse/journals-and-books. 

ERBF

European rare bone forum is a patient-led forum and networking arena between Patient Organisations, Scientific Societies and Industry working in Rare Bone conditions with the aim discuss and network, fostering early collaborations, improve health outcomes and care for people living with rare bone conditions and empower the rare bone community across Europe.

European registries for Rare Bone and Mineral Conditions

The European Registries for Rare Bone and Mineral Conditions (EuRR-Bone) aim to support the needs of the endocrine and bone community by facilitating the collaboration between patients, health care professionals and researchers across Europe and beyond. EuRR-Bone offers two open access platforms to capture rare conditions covered within the reference networks ERN BOND and Endo-ERN. The registries are open to all professionals involved in the care of these conditions. 

ICCBH

International Conference on Children’s Bone Health (ICCBH)

ICCBH is your opportunity to hear about and discuss the newest developments in our understanding of paediatric bone health and disease. The biennial ICCBH conference is attended by over 600 delegates from across the globe, making it truly multinational and multidisciplinary – a unique networking opportunity.

Upcoming events:

10th International Conference on Children’s Bone Health
2-5 July 2022, Dublin, Ireland
ICCBH Bone School
29 June to 1 July 2022, Dublin, Ireland
A 3-day educational course on paediatric bone health and rare bone diseases

14th International Conference on Osteogenesis Imperfecta
30 August to 2 September 2022, Sheffield, UK
ICCBH New Investigator Networking Group
Aims: To keep the community connected and support career development.
Target audience: Early career clinical and basic researchers with focus on paediatric bone health from anywhere in the world.
To find out more please contact the NI group organisers: Adi Raimann and Marie-Eve Robinson at iccbh-ni@googlegroups.com.

www.iccbh.org

IFMRS

The IFMRS is an international, not-for-profit federation of musculoskeletal research societies. Our purpose is to promote excellence in the field of musculoskeletal science, in order to improve the prevention and treatment of all musculoskeletal conditions worldwide.

We do this by collaborating with, and fostering collaboration between, local, regional and international organizations to share information and resources, raise public awareness, influence policy and provide education.

We bring together major musculoskeletal research societies from across the world, with a combined membership of over 15,000.

Inozyme Pharma, inc.

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy, INZ-701, to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies.

Ipsen

Ipsen is a leading global biopharmaceutical company focused on innovation and Specialty Care. It develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Active in the rare diseases field for many years, Ipsen brings scientific advancements to patients and invests significantly in R&D, leveraging global expertise and a local presence. Ipsen is committed to making innovative new treatments available to people living with rare diseases.
For more information on Ipsen, please visit www.ipsen.com. 

Nestle Nutrition a division of Nestlé Enterprise S.A.

The Nestlé Nutrition Institute (NNI), as a non for profit association in Switzerland, shares leading science based information and education with practicing health professionals in all parts of the world.

NNI is committed to foster the highest levels of discussion within scientific community and build nutrition knowledge globally. All NNI exclusive resources are available at http://www.nestlenutrition-institute.org.

Osteogenesis Imperfecta Federation Europe (OIFE)

“Osteogenesis Imperfecta Federation Europe (OIFE) is an umbrella association for 37 organizations dealing with the rare condition Osteogenesis Imperfecta (OI) also known as brittle bone disease.
Our mission is to connect and empower organizations, professionals and individuals to improve lives of people with OI.
OIFE’s ordinary member organizations are European and our main activities are based in Europe. But we collaborate with OI-organizations around the world with the intention to exchange ideas, information and best practices.
OIFE is a member of EURORDIS – the umbrella for rare disease organizations in Europe.”

 Pharmatest

PHARMATEST is a preclinical CRO offering in vitro assays, in vivo efficacy models and ex vivo bone analysis services in the fields of skeletal diseases and oncology.
We are the leading experts in combining bone biology and cancer by having special expertise in bone metastases.

Our models of skeletal diseases include osteoclast and osteoblast in vitro studies and animal models of osteoporosis, osteoarthritis and rare bone disease.
Ex vivo services cover complete histomorphometry and non-invasive imaging for bone and soft tissue and large panel of biomarkers for preclinical and clinical samples.

Scanco Medical AG 

Scanco Medical AG (www.scanco.ch), established 1988, is a global provider of microCT, VivaCT and XtremeCT (HR-pQCT) systems as well as scan/analysis services. Systems are bundled with sophisticated, easy to use, analysis and visualization software as well as automatic specimen changers (specimen systems only).

Scanco Medical is the only company which offers a fully integrated optional Finite Element Analysis Software package with its systems. Optional hardware include a mechanical testing stage and GPU reconstruction engine.

Scanco Medical is also pleased to announce the availability of complete Windows® based systems beginning 2021. We wish all ECTS participants the best for the future.

Stratec Medizintechnik 

Stratec Medizintechnik is the producer of pQCT-based bone densitometry scanners. Results are presented in real density units (g/cm³). Additionally, geometrical properties of bone can be analysed which allow the estimation of mechanical properties. The combined analysis of muscle and bone allows differentiation of disuse osteopenia from true osteoporosis.

The sister company Novotec Medical is manufacturer of Galileo vibration training devices for muscle stimulation and of Leonardo motion analysis systems (mechanography). The side alternating technology employs a natural movement similar to human gait. Improvement of muscle function, treatment of back pain and immobility are typical fields of application.

UCB 

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
With 7 500 people in approximately 40 countries, UCB is continuously working to advance science and embrace new knowledge.
We are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology.
Patients inspire us to bring them value through cutting-edge science, innovative drugs, and practical solutions – so that they and their carers can get on with their lives.